Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ati-450
2. Zunsemetinib [inn]
3. Ati450
4. Cdd450
5. Zunsemetinib [usan]
6. Cdd-450
7. Ax2vwg0zcr
8. (1(2h),4'-bipyridin)-2-one, 3-chloro-4-((3,5-difluoro-2-pyridinyl)methoxy)-2'-(2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl)-5',6-dimethyl-, (-)-
9. (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2h-(1,4'-bipyridin)-2-one
10. 1640282-42-3
11. Unii-ax2vwg0zcr
12. Zunsemetinib [usan:inn]
13. Ati 450
14. Ati 450 [who-dd]
15. Chembl3704901
16. Schembl16279876
17. Gtpl11681
18. Bdbm175242
19. Ex-a6292
20. Who 11983
21. Hy-139553
22. Cs-0204147
23. Us9115089, 49
24. 1639791-42-6
25. 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-[2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl]-6-methylpyridin-2-one
| Molecular Weight | 513.9 g/mol |
|---|---|
| Molecular Formula | C25H22ClF2N5O3 |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 6 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 101 |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 888 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Zunsemetinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zunsemetinib, including repackagers and relabelers. The FDA regulates Zunsemetinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zunsemetinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Zunsemetinib supplier is an individual or a company that provides Zunsemetinib active pharmaceutical ingredient (API) or Zunsemetinib finished formulations upon request. The Zunsemetinib suppliers may include Zunsemetinib API manufacturers, exporters, distributors and traders.
Zunsemetinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zunsemetinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zunsemetinib GMP manufacturer or Zunsemetinib GMP API supplier for your needs.
A Zunsemetinib CoA (Certificate of Analysis) is a formal document that attests to Zunsemetinib's compliance with Zunsemetinib specifications and serves as a tool for batch-level quality control.
Zunsemetinib CoA mostly includes findings from lab analyses of a specific batch. For each Zunsemetinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zunsemetinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Zunsemetinib EP), Zunsemetinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zunsemetinib USP).
LOOKING FOR A SUPPLIER?
